Evidence map›Paper›PMID 20422012›Full record

ArticlePloS one2010

The coordinated p53 and estrogen receptor cis-regulation at an FLT1 promoter SNP is specific to genotoxic stress and estrogenic compound.

Yari Ciribilli, Virginia Andreotti, Daniel Menendez, Jan-Stephan Langen, Gilbert Schoenfelder, Michael A Resnick, Alberto Inga

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The p53-estrogen receptor loop in cancer.Current molecular medicine · 2013
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Yari CiribilliUnit of Molecular Mutagenesis and DNA Repair, National Institute for Cancer Research, IST, Genoa, Italy.
Virginia Andreotti
Daniel Menendez
Jan-Stephan Langen
Gilbert Schoenfelder
Michael A Resnick
Alberto Inga
National Institute of Environmental Health Sciences · USCharité - Universitätsmedizin Berlin · DEUniversity of Trento · ITUniversity of Würzburg · DE

Funding

Human Genes Affecting Chromosome Metabolism and Stress ResponseZIAES065079 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI MENENDEZ RENDON, DANIEL · 2009 to 2021
$12.5M
ISOLATION &CHARACTERIZATION OF GENES AFFECTING YEAST CHROMOSOME METABOLISMZ01ES065079 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI RESNICK, MICHAEL A · 1994 to 2008
$1.8M
Intramural NIH HHS Z01 ES065079NIEHS NIH HHS 1 Z01ES065079
6 · The paper itself

Abstract

backgroundRecently, we established that a C>T single nucleotide polymorphism (SNP) in the promoter of the VEGF receptor FLT1 gene generates a (1/2) site p53 response element (RE-T) that results in p53 responsiveness of the promoter. The transcriptional control required an estrogen receptor (ER) (1/2) site response element (ERE1) 225 nt upstream to the RE-T. METHODOLOGY/PRINCIPAL

findingsHere we report the identification of a second ER (1/2) site (ERE2) located 145 bp downstream of the RE-T and establish that both EREs can impact p53-mediated transactivation of FLT1-T in a manner that is cell type and ER level dependent. Gene reporter assays and ChIP experiments conducted in the breast cancer-derived MCF7 cells revealed that the ERE2 site was sufficient for p53-mediated ERalpha recruitment and transactivation of the FLT1-T promoter/reporter construct. Surprisingly, unlike the case for other p53 target promoters, p53-mediated transactivation of FLT1-T constructs or expression of the endogenous FLT1 gene, as well as binding of p53 and ER at the promoter constructs, was inducible by doxorubicin but not by 5-fluorouracil. Furthermore, ER activity at FLT1-T was differentially affected by ER ligands, compared to a control TFF1/pS2 ER target promoter. The p53-related transcription factors (TFs) p73 and p63 had no effect on FLT1 transactivation. CONCLUSIONS/SIGNIFICANCE: We establish a new dimension to the p53 master regulatory network where p53-mediated transcription from a (1/2) site RE can be determined by ER binding at one or more cis-acting EREs in manner that is dependent on level of ER protein, the type of ER ligand and the specific p53-inducing agent.

Indexed as

Polymorphism, Single NucleotideCell Line, TumorDNA DamageDoxorubicinEnhancer Elements, GeneticEstrogensFluorouracilGene Expression RegulationGene Regulatory NetworksHumansPromoter Regions, GeneticReceptors, EstrogenResponse ElementsTranscriptional ActivationTumor Suppressor Protein p53Vascular Endothelial Growth Factor Receptor-1DoxorubicinEstrogensFLT1 protein, humanFluorouracilReceptors, EstrogenTumor Suppressor Protein p53Vascular Endothelial Growth Factor Receptor-1

Identifiers

PMID20422012
PMCPMC2858160
OpenAlexW1967529389

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.